CAR-T therapy for hard-to-treat acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of cell therapy, called CAR-T, that uses your own immune cells to find and attack leukemia cells. It's designed for people whose AML has come back or hasn't responded to standard treatments. The cells are modified to target a protein called CD33 on leukemia cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of acute myeloid leukemia (AML) that has come back after treatment or hasn't responded to two rounds of standard therapy.
- Your leukemia cells show a specific marker (CD33) in at least 80% of tests.
- You are between 14 and 75 years old.
- You are generally able to care for yourself (performance status 0-2).
- Your heart, liver, and kidney function are within acceptable limits, and you have enough red blood cells (or can receive transfusions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cell therapy called CD33 CAR-T for people whose acute myeloid leukemia has come back or isn't responding to standard treatments. The goal is to see if it's safe and can help eliminate leukemia cells that carry the CD33 protein.
This trial tests a new type of CAR-T cell therapy that targets two proteins on leukemia cells (called CLL1 and CD33). The goal is to help people with acute myeloid leukemia that has relapsed or not responded to standard treatments.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This Phase 1 study tests a personalized immune-cell treatment (CD33 CAR T cells) for adults with AML that has returned or did not respond to treatment. It aims to see how safe the therapy is and how well it works for AML cells that carry the CD33 marker.
This trial tests a new approach for people with acute myeloid leukemia (AML) that has not gotten better with standard treatments. First, you receive modified stem cells, then specially designed immune cells (CAR T cells) that target a protein called CD33 on leukemia cells. The goal is to see if this combination can safely help your body fight the leukemia.
This trial tests a new type of cell therapy using natural killer (NK) cells that target a protein called CD33 found on AML cells. The goal is to see if these cells can help treat leukemia that has not responded to standard treatments, and you would receive a stem cell transplant afterward to help your bone marrow recover.
Hear when a new CAR-T Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.